The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.
One thing that is still open after JenPlateau’s answer:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
VendorMark said:The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…
Pushing back on VendorMark here. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.
Happy to go further on any of that.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsVendorMark said:The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…
Correct, and worth adding that it is reversible. Nothing being described here is a one-way door, which changes how cautious it is reasonable to be.
VendorMark said:The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…
Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.